Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.80 |
| ▸ | HTR6 | P50406 | 19/20 | 0.73 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 1/20 | 0.57 |
| ▸ | HTR1E | P28566 | 1/20 | 0.57 |
| ▸ | HTR1F | P30939 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485879 | 1.00 | MTNR1A (0.80) | MTNR1AHTR6HTR1ADRD2HTR1D | |
| SCHEMBL30859492 | 0.91 | HTR6 (0.75) | MTNR1AHTR6HTR1ADRD2HTR1D | |
| SCHEMBL24877632 | 0.91 | HTR6 (0.75) | MTNR1AHTR6HTR1ADRD2HTR1D | |
| SCHEMBL24877695 | 0.90 | HTR6 (0.74) | MTNR1AHTR6HTR1ADRD2HTR1D | |
| SCHEMBL29261926 | 0.90 | HTR6 (0.77) | MTNR1AHTR6HTR1ADRD2HTR1D | |
| SCHEMBL25624246 | 0.90 | MTNR1A (0.65) | MTNR1AHTR6HTR1ADRD2HTR1D | |
| SCHEMBL24877195 | 0.89 | HTR6 (0.72) | MTNR1AHTR6HTR1ADRD2HTR1D | |
| SCHEMBL5616413 | 0.89 | MTNR1A (1.00) | MTNR1AHTR6HTR1ADRD2HTR1D | |
| SCHEMBL30485892 | 0.88 | HTR6 (0.74) | MTNR1AHTR6HTR1ADRD2HTR1D | |
| SCHEMBL24878174 | 0.88 | HTR6 (0.74) | MTNR1AHTR6HTR1ADRD2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956991-A | N, N-dimethyltryptamine and related hallucinogens and uses thereof | 人类生物科学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230212119-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212119-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023283364-A2 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDLICS AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212119-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | PNMT, HTR5A, HNMT | MTNR1A 39/4885HTR6 9/4885HTR1A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.